Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of non-alcoholic steatohepatitis or fatty liver disease (NASH)

Trial Profile

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of non-alcoholic steatohepatitis or fatty liver disease (NASH)

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2018

At a glance

  • Drugs Foralumab (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Oct 2018 New trial record
    • 24 Sep 2018 According to a Tiziana Life Sciences media release, the company plans to submit an additional IND application to administer oral formulation of Foralumab the treatment of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis or fatty liver disease (NASH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top